The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Antiviral therapy for human immunodeficiency virus infections
Open accessAbstract
Depending on the stage of their intervention with the viral replicative cycle, human immunodeficiency virus inhibitors could be divided into the following groups: (i) adsorption inhibitors (i.e., CD4 constructs, polysulfates, polysulfonates, polycarboxylates, and polyoxometalates), (ii) fusion inhibitors (i.e., plant lectins, succinylated or aconitylated albumins, and betulinic acid derivatives), (iii) uncoating inhibitors (i.e., bicyclams), (iv) reverse transcription inhibitors acting either competitively with the substrate binding site (i.e., dideoxynucleoside analogs and acyclic nucleoside phosphonates) or allosterically with a nonsubstrate binding site (i.e., non-nucleoside reverse transcriptase inhibitors), (v) integration inhibitors, (vi) DNA replication inhibitors, (vii) transcription inhibitors (i.e., antisense oligodeoxynucleotides and Tat antagonists), (viii) translation inhibitors (i.e., antisense oligodeoxynucleotides and ribozymes), (ix) maturation inhibitors (i.e., protease inhibitors, myristoylation inhibitors, and glycosylation inhibitors), and finally, (x) budding (assembly/release) inhibitors. Current knowledge, including the therapeutic potential, of these various inhibitors is discussed. In view of their potential clinical the utility, the problem of virus-drug resistance and possible strategies to circumvent this problem are also addressed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
Furman, P. A., Fyfe, J. A., St Clair, M. H., Weinhold, K., Rideout, J. L., Freeman, G. A., Lehrman, S. N., Bolognesi, D. P., Broder, S., & Mitsuya, H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8333 · Cited by 1,347
Göttlinger, H. G., Sodroski, J. G., & Haseltine, W. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5781 · Cited by 841
Bushman, F. D., & Craigie, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1339 · Cited by 410
Inhibition of HIV Infection by Caffeoylquinic Acid Derivatives
Mahmood, N., Moore, P. S., De Tommasi, N., De Simone, F., Colman, S., Hay, A. J., & Pizza, C. (1993) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632029300400406 · Cited by 119
Cited by
Plant Products as Antimicrobial Agents
Cowan, M. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.564 · Cited by 9,043
Wang, J., Morin, P., Wang, W., & Kollman, P. A. (2001) · Journal of the American Chemical Society · doi:10.1021/ja003834q · Cited by 708
Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells
Zuco, V., Supino, R., Righetti, S. C., Cleris, L., Marchesi, E., Gambacorti-Passerini, C., & Formelli, F. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00718-2 · Cited by 530
De Clercq, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1134 · Cited by 460
Self-citationDe Clercq, E. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00025-4 · Cited by 358
Self-citation
Metadata
- Authors
- De Clercq, E.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1995-04
- Volume
- 8
- Issue
- 2
- Pages
- 200-239
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2148698673
- Cited by
- 246
- References
- 5
- FWCI
- 21.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiviral therapy for human immunodeficiency virus infections. https://app.cochat.ai/papers/10.1128/cmr.8.2.200
- The paper
- De Clercq, E. (1995). Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews. https://doi.org/10.1128/cmr.8.2.200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.